FTC Letters On Ambien CR Agreements Are "Educational" And A "Warning" For Industry
This article was originally published in The Pink Sheet Daily
FTC's rebukes Sanofi, Watson and Synthon for failing to report agreements related to generic challenges of the insomnia drug, but Bureau of Competition Director Feinstein notes that the Commission is not seeking to fine the firms.
You may also be interested in...
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.